Kardatuxan (Rivaroxaban)

Kardatuxan is a direct Factor Xa inhibitor used in several thromboembolic conditions.

• Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism.
• Deep vein thrombosis (DVT) and pulmonary embolism (PE): treats acute events and prevents recurrence.
• Orthopedic surgery prophylaxis: lowers incidence of postoperative DVT.

• Rivaroxaban binds directly to the active site of coagulation factor Xa, inhibiting both free and clot‑bound forms. This blockade prevents conversion of prothrombin to thrombin, thereby reducing thrombin generation and subsequent fibrin clot formation without requiring antithrombin as a cofactor.

Rivaroxaban may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Minor gastrointestinal upset: nausea, dyspepsia, or abdominal pain.
• Mild bruising or bleeding: easy bruising, epistaxis, or gum bleeding.
• Headache: transient, low‑intensity.
• Dizziness: occasional light‑headedness.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Major hemorrhage: intracranial, gastrointestinal or fatal bleeding.
• Hematoma: large, painful collections at injection or trauma sites.
• Hepatic injury: elevated liver enzymes or hepatitis.
• Allergic reaction: anaphylaxis, angioedema, or severe rash.
• Thrombocytopenia: low platelet count leading to bleeding risk.

Before prescribing Kardatuxan, clinicians should evaluate patient‑specific risk factors and monitor for bleeding.

• Renal impairment: adjust use or avoid in severe dysfunction.
• Hepatic disease: avoid in patients with active liver disease or significant impairment.
• Concomitant anticoagulants: avoid combination with other anticoagulants or antiplatelet agents unless medically justified.
• Surgery or invasive procedures: discontinue according to recommended timing to reduce peri‑operative bleeding.
• Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid)

• Strong CYP3A4 and P‑glycoprotein inhibitors (e.g., ketoconazole, ritonavir): may markedly increase plasma concentrations.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy and increase clot risk.
• Concurrent use with other anticoagulants or antiplatelet agents (e.g., warfarin, clopidogrel): heightens bleeding risk.

Moderate Interactions (Monitor Closely)

• NSAIDs and selective COX‑2 inhibitors: increase gastrointestinal bleeding potential.
• SSRIs, SNRIs, or other serotonergic agents: may modestly raise bleeding tendency.
• Antifungals (e.g., fluconazole) and certain antibiotics (e.g., clarithromycin): can elevate rivaroxaban levels, requiring clinical monitoring.